Meet us at…
Latest news
OTR3 announces first patient enrollment in its pivotal study “MATRISCAR”, a double blind placebo-controlled study aimed at demonstrating the effects of CACIPLIQ20 on Post-surgical Scars
26 January 2023
Isabelle Barbosa, Christophe Morin, Stephanie Garcia, Arlette Duchesnay, Mustapha Oudghir, Guido Jenniskens, Hua-Quan Miao, Scott Guimond, Gilles Carpentier, José Cebrian, Jean-Pierre Caruelle, Toin van Kuppevelt, Jeremy Turnbull, Isabelle Martelly, Dulce Papy-Garcia Abstract Crucial events in myogenesis rely on the highly regulated spatiotemporal distribution of cell surface heparan sulfate proteoglycans to [...]
31 May 2022
OTR3 receives approval from ANSM to start new clinical trial with the application of a RGTA® product in ischemic stroke.
8 October 2021
OTR3 appoints new management teams as the company planned to launch a second generation of RGTA® products.
29 June 2021
Cacipliq 20® - Ischemic wound First Clinical Pilot Study on critical ischemic leg ulcers with Matrix Therapy ReGeneraTing Agent (RGTA ® ) technology P. DESGRANGES, T. LOUISSAINT, E. ALLAIRE, B. GODEAU, K. KICHENIN, J.- P. BECQUEMIN, D. BARRITAULT Patients with non-healing leg ulcers due to severe limb ischemia and [...]
15 February 2019
Cacipliq 20® - Chronic wound Regenerating matrix-based therapy for chronic wound healing: a prospective within-subject pilot study Groah SL, Libin A, Spungen M, Nguyen KL, Woods E, Nabili M, Ramella-Roman J, Barritault D. The aim of this study was to determine whether a skin-specific bioengineered regenerating agent (RGTA) heparan [...]
15 February 2019
